We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.9B
1-Year Est. Return 169.69%
This Fund
S&P 500
This Quarter Est. Return
+16.74%
1 Year Est. Return
+169.69%
3 Year Est. Return
+507.65%
5 Year Est. Return
+746.04%
10 Year Est. Return
–
AUM
$189M
AUM Growth
+$13.2M
Cap. Flow
+$14.6M
Cap. Flow %
7.75%
Top 10 Hldgs %
41.3%
Holding
80
New
19
Increased
18
Reduced
20
Closed
17

Top Buys

Rank Stock Value
1
MRSN
Mersana Therapeutics
MRSN
+$7.94M
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$7.37M
3
LNTH icon
Lantheus
LNTH
+$6.99M
4
NTRA icon
Natera
NTRA
+$5.75M
5
CMPS
Compass Pathways
CMPS
+$5.64M

Top Sells

Rank Stock Value
1
ZYME icon
Zymeworks
ZYME
+$11.4M
2
AZN icon
AstraZeneca
AZN
+$7.06M
3
PRTA icon
Prothena Corp
PRTA
+$7.06M
4
SYRE icon
Spyre Therapeutics
SYRE
+$3.42M
5
LLY icon
Eli Lilly
LLY
+$3.41M

Sector Composition

Rank Sector Weight
1 Healthcare 98.5%
2 Real Estate 0.86%
3 Miscellaneous 0.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EPIX
1
DELISTED
ESSA Pharma
EPIX
$12.6M 6.68%
1,826,980
-255,205
-12% -$1.73M
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$9.51M 5.04%
1,685,879
+59,178
+4% +$282K
OSUR icon
3
OraSure Technologies
OSUR
$239M
$7.61M 4.03%
625,109
+401,909
+180% +$5.49M
MRSN
4
DELISTED
Mersana Therapeutics
MRSN
$7.32M 3.88%
+15,722
New +$7.94M
INBX
5
DELISTED
Inhibrx, Inc. Common Stock
INBX
$7.32M 3.88%
+406,500
New +$7.37M
NTRA icon
6
Natera
NTRA
$50.6B
$7.3M 3.87%
+101,089
New +$5.75M
QDEL icon
7
QuidelOrtho
QDEL
$729M
$6.75M 3.58%
30,751
-149
-0.5% -$33.3K
VCEL icon
8
Vericel Corp
VCEL
$2.03B
$6.54M 3.47%
353,006
+114,474
+48% +$1.89M
IMMU
9
DELISTED
Immunomedics Inc
IMMU
$6.49M 3.44%
76,268
-42,732
-36% -$2.16M
SRPT icon
10
Sarepta Therapeutics
SRPT
$2.19B
$6.48M 3.44%
46,166
+11,666
+34% +$1.77M
LNTH icon
11
Lantheus
LNTH
$6.58B
$6.46M 3.42%
+509,544
New +$6.99M
NVCR icon
12
NovoCure
NVCR
$1.88B
$5.83M 3.09%
52,377
-4,020
-7% -$321K
TCRR
13
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$5.73M 3.04%
+282,041
New +$4.95M
XENE icon
14
Xenon Pharmaceuticals
XENE
$5.45B
$5.54M 2.94%
500,264
+249,367
+99% +$2.93M
CMPS
15
Compass Pathways
CMPS
$1.91B
$5.48M 2.9%
+156,982
New +$5.64M
IRMD icon
16
iRadimed
IRMD
$1.05B
$4.25M 2.25%
198,739
-13,697
-6% -$308K
ZYME icon
17
Zymeworks
ZYME
$1.86B
$4.16M 2.2%
89,233
-331,603
-79% -$11.4M
HZNP
18
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$4.06M 2.15%
52,227
+22,627
+76% +$1.56M
CRDF icon
19
Cardiff Oncology
CRDF
$104M
$4M 2.12%
+281,819
New +$1.86M
EIGR
20
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$3.85M 2.04%
15,752
-4,924
-24% -$1.53M
ADVM
21
DELISTED
Adverum Biotechnologies
ADVM
$3.75M 1.99%
36,435
+14,563
+67% +$2.18M
ALXN
22
DELISTED
Alexion Pharmaceuticals
ALXN
$3.44M 1.82%
30,077
-20,712
-41% -$2.23M
BIIB icon
23
Biogen
BIIB
$31.9B
$3.28M 1.74%
11,556
+9,256
+402% +$2.58M
OSH
24
DELISTED
Oak Street Health, Inc.
OSH
$3.15M 1.67%
+58,892
New +$2.64M
DXCM icon
25
DexCom
DXCM
$32.6B
$3.13M 1.66%
30,332
-7,868
-21% -$822K
1
2 3 4

Similar funds

GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return
7WCP
71 West Capital Partners Boston, Massachusetts $2.89B AUM
ACM
Aquatic Capital Management Chicago, Illinois $2.91B AUM 27.09% 1-Year Est. Return
HWA
Heritage Wealth Advisors Richmond, Virginia $2.91B AUM 24.25% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.89B AUM 29.25% 1-Year Est. Return
WPW
Waldron Private Wealth Bridgeville, Pennsylvania $2.89B AUM 23.18% 1-Year Est. Return
BWL
Bogart Wealth LLC Mclean, Virginia $2.92B AUM 23.85% 1-Year Est. Return

Soleus Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Soleus Capital Management held 80 positions worth $189M, up 7.5% from $175M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Soleus Capital Management deployed $14.6M of net new capital in Q3 2020, opening 19 new positions and adding to 18 existing holdings. Its largest new stake was Mersana Therapeutics: 15,722 shares worth $7.32M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 92% a quarter earlier, followed by Real Estate and Miscellaneous.

On the sell side, the largest reduction was Zymeworks, an estimated $11.4M trimmed.

  • Soleus Capital Management's largest Q3 2020 buy was Mersana Therapeutics: 15,722 shares worth $7.32M.
  • Soleus Capital Management added most to OraSure Technologies in Q3 2020, an estimated $5.49M increase.
  • Soleus Capital Management's biggest Q3 2020 reduction was Zymeworks, cutting an estimated $11.4M.
  • Soleus Capital Management fully exited Prothena Corp in Q3 2020, selling an estimated $7.06M.
  • Soleus Capital Management's ten largest holdings make up 41% of its $189M portfolio in Q3 2020.
  • Soleus Capital Management opened 19 new positions and closed 17 in Q3 2020.
  • Soleus Capital Management's portfolio value rose 7.5% quarter-over-quarter to $189M.

Based on Soleus Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.